Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJonsson Comprehensive Cancer Center
About this trial
This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.
Eligibility criteria
Qualifiers
Elected to undergo interstitial brachytherapy as part of conventional treatment for renal cell carcinoma
Biopsy proven renal cell carcinoma
No definitive evidence of locally advanced (nodal or tumor thrombus) or distant (metastatic) disease
Lesion size (maximal dimension) of 4 to 10 cm
Disqualifiers
Presence of an active, untreated, non-renal malignancy
Uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction within 6 months
History of bleeding diathesis or recent bleeding episode
Need for urgent treatment of renal cancer due bleeding, pain, or paraneoplastic syndrome
Trial design
Treatments tested in this trial
- Interstitial Radiation Therapy
Treatment groups
17 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov